Bharat Biotech seeks nod for phase-3 trials of intranasal COVID-19 vaccine as booster dose
By, Admin1 min read
Share
Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its COVID19 intranasal vaccine (BBV154) to use as booster dose, sources said on Monday.
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
